YAFI Online Programming // Disease State Management and Drug Therapy
Sickle Cell Disease
Dispelling Myths, Making Clinical Progress
After participating in this activity, pharmacists will be able to:
- Describe SCD’s different phenotypes and implications for therapy
- Classify the new therapies for adult and pediatric SCD patients
- Describe the pharmacist’s responsibilities and opportunities in management of SCD patients
- Review investigational agents in the pipeline for SCD
- After completing this continuing education activity, pharmacy technicians will be able to
- Compare the cost savings of newer agents to the standard of care—hydroxyurea
- Describe SCD’s different phenotypes and implications for therapy
- Determine when to refer patients to the pharmacist for recommendations or referrals
Release Date: April 15, 2021
Expiration Date: April 15,2024
21YC13-BXV96 Pharmacy Technician
2.0 hours of CE
Sickle cell disease (SCD) is an inherited genetic disorder that affects the African American community disproportionally. Research has grown SCD knowledge by leaps and bounds from Dr. James Herrick’s description of peculiar shaped red blood cells in 1910 to the innovative CRISPR-cas9 technology. With a multifaceted pathophysiology triggered by a single amino acid substitution, SCD can cause varying degrees of chronic hemolytic anemia, vasculopathy, vaso-occlusive disease, and multiple-organ damage. Ultimately, it can shorten a patient’s life span.
Patients with SCD experience considerable barriers to therapy. Three key strategies for preventing SCD complications are screening, prevention of infection or vaso-occlusive crisis (VOC), and immunizations. This activity focuses on SCD’s complications and the therapeutic agents available to treat SCD.
|The University of Connecticut School of Pharmacy is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.|
Pharmacists and pharmacy technicians are eligible to participate in this application-based activity and will receive up to 0.2 CEU (2 contact hours) for completing the activity, passing the quiz with a grade of 70% or better, and completing an online evaluation. Statements of credit are available via the CPE Monitor on- line system and your participation will be recorded with CPE Monitor within 72 hours of submission
Grant funding: Novartis
Initial Release Date: April 15, 2021
Expiration Date: April 15, 2024
To obtain CPE credit, visit the UConn Online CE Center
Use your NABP E-profile ID and the session code 21YC13-XRT83 for pharmacists or 21YC13-BXV96 for pharmacy technicians to access the online quiz and evaluation.
First- time users must pre-register in the Online CE Center. Test results will be displayed immediately and your participation will be recorded with CPE Mon- itor within 72 hours of completing the requirements.
For questions concerning the online CPE activities, email firstname.lastname@example.org
Bisni Narayanan, Pharm D, MS, Pharmacy Supervisor- Operations, Yale New Haven Health Systems, Outpatient Pharmacy Services, Hamden, CT
The author has no actual or potential financial conflicts of interest associated with this article.
Disclosure of Discussions of Off-label and Investigational Drug Use
This activity may contain discussion of off label/unapproved use of drugs. The content and views presented in this educational program are those of the faculty and do not necessarily represent those of the University of Connecticut School of Pharmacy. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Sickle cell disease (SCD) is an inherited, lifelong blood disorder causing severe complications involving multiple organ systems. SCD affects approximately 100,000 Americans.1 Disproportionately affecting the Black or African American community, 1 of every 365 Black or African American babies is born with SCD. About 1 in 13 Black or African American babies is born with sickle cell trait, meaning they carry the gene mutation but do not express the disease (see SIDEBAR). Physician James Herrick described SCD about 100 years ago after observing a case of severe malaise and anemia in a young dental student from Grenada.2 Linus Pauling’s discovery of the abnormal protein hemoglobin S as the cause of SCD paved the way for treating SCD as a “molecular disease.”
Full List of References
1. Centers for Disease Control and Prevention. Data & statistics on sickle cell disease. Available at https://www.cdc.gov/ncbddd/sicklecell/data.html. Accessed March 21,
2. Savitt TL, Goldberg MF. Herrick's 1910 case report of sickle cell anemia. The rest of the story. JAMA. 1989;261(2):266-271.
3. Naik RP, Haywood C Jr. Sickle cell trait diagnosis: clinical and social implications. Hematology Am Soc Hematol Educ Program. 2015;2015(1):160-167.
4. Darbari DS, Sheehan VA, Ballas SK. The vaso-occlusive pain crisis in sickle cell disease: Definition, pathophysiology, and management. Eur J Haematol. 2020;105(3):237-246.
5. Salinas Cisneros G, Thein SL. Recent advances in the treatment of sickle cell disease. Front Physiol. 2020;11:435.
6. Pecker LH, Lanzkron S. Sickle cell disease. Ann Intern Med. 2021;174(1):ITC1-ITC16.
7. Farooq F, Mogayzel PJ, Lanzkron S, et al. Comparison of US federal and foundation funding of research for sickle cell disease and cystic fibrosis and factors associated with research productivity. JAMA Netw Open. 2020;3(3):e201737.
8. Centers for Disease Control and Prevention. Sickle cell disease monitoring. Available at https://www.cdc.gov/ncbddd/sicklecell/features/sickle-cellawareness.html. Accessed March 20, 2021.
9. Kumar V, Chaudhary N, Achebe MM. Epidemiology and predictors of all-cause 30-day readmission in patients with sickle cell crisis. Sci Rep. 2020;10(1):2082.
10. Kaur M, Brown M, Love TW, et al. Understanding sickle cell disease: impact of surveillance and gaps in knowledge. Blood Adv.
11. Bender MA. Sickle Cell Disease. In: Adam MP, Ardinger HH, Pagon RA, et al., eds. GeneReviews®. Seattle (WA): University of Washington,
Seattle; September 15, 2003.
12. U.S. Department of Health and Human Services. Report on pain
management best practices: Updates, gaps, inconsistencies, and recommendations. Available at https://www.hhs.gov/ash/advisorycommittees/pain/reports/index.html. Accessed March 20, 2021.
13. National Heart, Lung, and Blood Institute. Evidence-based management of sickle cell disease: Expert panel report, 2014. Available at
http://www.nhlbi.nih.gov/health-pro/guidelines/sickle-cell-diseaseguidelines. Accessed March 22. 2021.
14. Brandow AM, Carroll CP, Creary S, et al. American Society of Hematology 2020 guidelines for sickle cell disease: management of acute and
chronic pain. Blood Adv. 2020;4(12):2656-2701.
15. DeBaun RM, Vichinsky PE. Acute vaso-occlusive pain management
in sickle cell disease In: Mahoney HD, ed. UpToDate; 2021. Available at
www.uptodate.com. Accessed March 20, 2021.
16. Field J, Vichinsky PE. Overview of the management and prognosis of
sickle cell disease. In: Tirnauer J, ed. UpToDate; 2021. Available at
www.uptodate.com. Accessed March 20, 2021.
17. Kane I, Nagalli S. Splenic Sequestration Crisis. In: StatPearls. Treasure Island (FL): StatPearls Publishing; July 6, 2020.
18. Abboud MR. Standard management of sickle cell disease complications. Hematol Oncol Stem Cell Ther. 2020;13(2):85-90.
19. Eaton WA, Bunn HF. Treating sickle cell disease by targeting HbS polymerization. Blood. 2017;129(20):2719-2726.
20. McGann PT, Ware RE. Hydroxyurea therapy for sickle cell anemia.
Expert Opin Drug Saf. 2015;14(11):1749-1758.
21. Wang WC, Ware RE, Miller ST, et al. Hydroxycarbamide in very
young children with sickle-cell anaemia: a multicentre, randomised,
controlled trial (BABY HUG). Lancet. 2011;377(9778):1663-1672.
22. Opoka RO, Ndugwa CM, Latham TS, et al. Novel use of hydroxyurea
in an African region with malaria (NOHARM): a trial for children with
sickle cell anemia. Blood. 2017;130(24):2585-2593.
23. Ware RE, Davis BR, Schultz WH, et al. Hydroxycarbamide versus
chronic transfusion for maintenance of transcranial doppler flow velocities in children with sickle cell anaemia-TCD With Transfusions Changing to Hydroxyurea (TWiTCH): a multicentre, open-label, phase 3,
non-inferiority trial. Lancet. 2016;387(10019):661-670.
24. Charache S, Barton FB, Moore RD, et al. Hydroxyurea and sickle cell
anemia. Clinical utility of a myelosuppressive "switching" agent. The
Multicenter Study of Hydroxyurea in Sickle Cell Anemia. Medicine (Baltimore). 1996;75(6):300-326.
25. Steinberg MH, McCarthy WF, Castro O, et al. The risks and benefits
of long-term use of hydroxyurea in sickle cell anemia: A 17.5 year follow-up. Am J Hematol. 2010;85(6):403-408.
26. John CC, Opoka RO, Latham TS, et al. Hydroxyurea dose escalation
for sickle cell anemia in sub-Saharan Africa. N Engl J Med.
27. Siklos [package insert]. Addmedica;2019.
28. Droxia [package insert]. Bristol-Myers Squibb Company;2012.
29. Oxbryta [package insert]. Global Blood Therapeutics, Inc;2019.
30. Vichinsky E, Hoppe CC, Ataga KI, et al. A phase 3 randomized trial of
voxelotor in sickle cell disease. N Engl J Med. 2019;381(6):509-519.
31. Endari [package insert]. Torrance, CA: Emmaus Medical, Inc;2017.
32. Niihara Y, Miller ST, Kanter J, et al. A phase 3 trial of l-glutamine in
sickle cell disease. N Engl J Med. 2018;379(3):226-235.
33. Adakveo [package insert]. Novartis Pharmaceuticals
34. Ataga KI, Kutlar A, Kanter J, Liles D, et al. Crizanlizumab for the prevention of pain crises in sickle cell disease. N Engl J Med.
35. Kutlar A, Kanter J, Liles DK, et al. Effect of crizanlizumab on pain crises in subgroups of patients with sickle cell disease: A SUSTAIN study
analysis. Am J Hematol. 2019;94(1):55-61.
36. ClinicalTrials.gov. Efficacy and safety of rivipansel (GMI-1070) in the
treatment of vaso-occlusive crisis in hospitalized subjects with sickle
cell disease. Available at https://clinicaltrials.gov/ct2/show/
NCT02187003. Accessed March 21, 2021.
37. Theodore Wun, M.D. Early initiation of treatment with rivipansel
for acute vaso-occlusive crisis in sickle cell disease (SCD) achieves earlier discontinuation of iv opioids and shorter hospital stay: Reset Clinical
Trial Analysis (abstract #678). Presentation at American Society of Hematology Annual Meeting and Exposition, December 5-8, 2020.
38. Adzu B, Masimirembwa C, Mustapha KB, et al. Effect of NIPRISAN®
on CYP3A4 activity in vitro. Eur J Drug Metab Pharmacokinet.
39. Oniyangi O, Cohall DH. Phytomedicines (medicines derived from
plants) for sickle cell disease. Cochrane Database Syst Rev.
40. Perampaladas K, Masum H, Kapoor A, et al. The road to commercialization in Africa: lessons from developing the sickle-cell drug Niprisan. BMC Int Health Hum Rights. 2010;10 Suppl 1(Suppl 1):S11.
41. Daak AA, Dampier CD, Fuh B, et al. Double-blind, randomized, multicenter phase 2 study of SC411 in children with sickle cell disease
(SCOT trial). Blood Adv. 2018;2(15):1969-1979.
42. Frangoul H, Altshuler D, Cappellini MD, et al. CRISPR-Cas9 Gene Editing for Sickle Cell Disease and beta-Thalassemia. N Engl J Med.
43. Pharmacist’s Letter. Management of Sickle Cell Disease. March
2020. Available at
015/Feb/Management-of-Sickle-Cell-Disease-8101. Accessed March 20,
44. Department of Health and Human Services – Division of Immunization. A quick look at vaccines needed for persons with sickle cell disease. May 17, 2019. Available at
55853_7.pdf. Accessed on March 21, 2021.